Rosecliff Acquisition Corp I

Q2 2026 R&D revenue was $3.5 million, down from $5.1 million in Q2 2025. Gross margin was 31.6% versus 45.2% a year ago, and gross margin for the first six months was 41.8% versus 46.4%. Operating expenses rose to $5.4 million from $4.4 million, and net loss improved to $4.2 million, or $0.13 per share, versus a $8.0 million loss, or $0.31 per share, in Q2 2025. Cash was $14 million as of June 30, 2026, total debt was $14.9 million, and management drew the second $6.5 million tranche of its Avenue Capital facility, bringing the commitment to $15 million. The company reiterated full-year 2026 revenue guidance of approximately $18.5 million, including the effect of new BARDA funding from March, and said that guidance does not include any significant contribution from DeepView system sales.

Vincent Capone framed the quarter as a transition from development to commercialization, with FDA clearance and new commercial leadership setting up the next phase. He emphasized a disciplined rollout, starting with up to 30 U.S. placements backed by BARDA, while also pursuing UKCA expansion and future indications such as critical limb ischemia, amputations, and diabetic foot ulcers. His tone was upbeat and confident, repeatedly stressing the technology’s novelty, clinical moat, and potential to become a platform company.

David McGuire described Q2 as a transitional quarter with lower development revenue because BARDA moved into a cost-sharing phase and major study work was between phases. He explained the drop in gross margin to 31.6% from 45.2% as a function of that BARDA cost share, while noting a third-party pricing study and early customer feedback suggest commercial pricing can support margins well above development levels. He also highlighted operating discipline, saying G&A excluding stock compensation was essentially flat year over year, and pointed to $14 million of cash, no principal payments due until March 2027, a March 2028 maturity on the Avenue facility, and access to BARDA and Yorkville capital as support for launch.

Analysts focused on how the company will actually execute commercialization, especially the size and readiness of the sales force, procurement hurdles at hospitals, and the role of BARDA in building relationships. Management said the sales team currently has two people, with budget for at least two more, and that procurement can take longer at new sites because of AI and cybersecurity committee reviews. On international expansion, Capone said the U.K. and Australia look like the first likely markets, with some interest in the Gulf region, but he avoided overpromising on timing. He also said BARDA is a funding partner, not a commercial introducer, and that the company’s own clinician relationships will drive adoption.